89,159 Shares in Sotera Health (NASDAQ:SHC) Bought by Cerity Partners LLC

Cerity Partners LLC acquired a new position in Sotera Health (NASDAQ:SHC - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 89,159 shares of the company's stock, valued at approximately $1,489,000.

Several other institutional investors and hedge funds have also recently modified their holdings of SHC. CWM LLC increased its position in Sotera Health by 86.1% in the second quarter. CWM LLC now owns 2,146 shares of the company's stock worth $25,000 after buying an additional 993 shares during the last quarter. GAMMA Investing LLC grew its position in Sotera Health by 125.0% during the third quarter. GAMMA Investing LLC now owns 2,988 shares of the company's stock worth $50,000 after buying an additional 1,660 shares in the last quarter. Point72 DIFC Ltd boosted its holdings in shares of Sotera Health by 556.6% in the 2nd quarter. Point72 DIFC Ltd now owns 6,540 shares of the company's stock worth $78,000 after purchasing an additional 5,544 shares in the last quarter. Capital Performance Advisors LLP purchased a new position in shares of Sotera Health in the 3rd quarter worth about $91,000. Finally, Acadian Asset Management LLC boosted its holdings in shares of Sotera Health by 728.0% in the 2nd quarter. Acadian Asset Management LLC now owns 9,381 shares of the company's stock worth $111,000 after purchasing an additional 8,248 shares in the last quarter. 91.03% of the stock is owned by hedge funds and other institutional investors.

Sotera Health Trading Up 3.5 %

SHC traded up $0.45 during midday trading on Wednesday, reaching $13.28. 2,508,816 shares of the company's stock traded hands, compared to its average volume of 1,347,193. The firm has a fifty day moving average of $15.04 and a two-hundred day moving average of $14.06. The stock has a market capitalization of $3.76 billion, a price-to-earnings ratio of 53.12 and a beta of 1.96. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61. Sotera Health has a 52 week low of $10.71 and a 52 week high of $17.44.

Sotera Health (NASDAQ:SHC - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The business had revenue of $285.47 million for the quarter, compared to the consensus estimate of $278.64 million. During the same period in the previous year, the company earned $0.18 EPS. The company's revenue for the quarter was up 8.5% on a year-over-year basis. On average, equities analysts anticipate that Sotera Health will post 0.61 earnings per share for the current fiscal year.

Insider Transactions at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the company's stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $15.03, for a total value of $150,300,000.00. Following the sale, the director now owns 49,215,301 shares in the company, valued at $739,705,974.03. This represents a 16.89 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 55.12% of the company's stock.

Wall Street Analysts Forecast Growth

SHC has been the subject of a number of research reports. Citigroup upped their price objective on Sotera Health from $18.00 to $20.00 and gave the stock a "buy" rating in a report on Wednesday, November 6th. Royal Bank of Canada reissued an "outperform" rating and issued a $17.00 target price on shares of Sotera Health in a research note on Thursday, November 21st. Finally, Barclays boosted their target price on Sotera Health from $14.00 to $17.00 and gave the company an "overweight" rating in a research note on Tuesday, August 6th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.50.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.